Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted ...

Acute myeloid leukemia (AML) is an aggressive bone marrow disease. Despite advances in treatment, AML remains a therapeutic challenge due to high rates of ...

A young man has been diagnosed with acute stage 3 leukemia and urgently needs help to survive. He has appealed to the general ...

The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia.

TUS+VEN+AZA triplet has potential as frontline therapy to treat large, mutationally diverse populations of AMLSAN DIEGO and ...

Vevoctadekin is under clinical development by Simcha Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.

LYT-200 is currently being evaluated in two Phase 1/2 trials for the potential treatment of AML/MDS and head and neck cancers PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company” ...

Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...

In a significant advancement for cancer research, a team of scientists from Max Planck Institute for Biology Tübingen, ...